In Other News

• Low-Cost, Simple-to-Use, Ultrafast Point-of-Care COVID-19 Test to Provide RT PCR Results in 8 Minutes

• Abbott Releases ID NOW COVID-19 Interim Clinical Study Results Confirming Test Sensitivity and Specificity

• BioFire Diagnostics’ PCR-based SARS-CoV-2 Test Receives FDA Emergency Use Authorization

• Thermo Fisher’s OmniPath COVID-19 Total Antibody ELISA Test for SARS-CoV-2 Granted FDA Emergency Use Authorization

• Hologic Aptima SARS-CoV-2 Assay’s FDA EUA Amended to Include COVID-19 Testing of Asymptomatic Individuals, Symptomatic Sample Pooling

• Mast Awarded Public Health England Tender for Exclusive Supply of AST and AMR Discs

• New Dipstick Technology Could Offer Faster, Cheaper and Mobile COVID-19 Diagnosis

• World’s First Assay Kit to Directly Profile SARS-CoV-2 Subgenomic RNA (sgRNA) from Clinical Samples Launched

• Novel Rapid Antigen Assay Detects SARS-CoV-2 in Saliva in 10 Minutes

• EKF Diagnostics’ PrimeStore MTM Successfully Evaluated by Public Health England for SARS-CoV-2 Inactivation

• US Labs Increase COVID-19 Testing Capacity but Facing Shortage of Supplies, Finds NILA Survey

• Abbott’s Panbio COVID-19 Ag Rapid Test Receives WHO Clearance for Emergency Use Listing

• Automatic Point-of-Care System Measures COVID-19 Antibodies Along with HbA1c, CRP, U-Albumin within 3 Minutes

• Qiagen to Complement COVID-19 Testing Portfolio with Novel Kit That Simplifies and Accelerates PCR Analysis for Research

• Bacteriophage Analysis Technique Reveals Details of COVID-19’s Impact on the Immune System

• New COVID-19 Testing Method Delivers Accurate Results Without Using Reagents

• New Sensor Rapidly Detects COVID-19 Infection Status, Severity, and Immunity

• Quidel Receives FDA EUA for First Rapid Antigen Combination ABC Test for Influenza A+B and COVID-19

• LabCorp’s Innovative SARS-CoV-2 RNA Extraction Method Secures FDA Emergency Use Authorization

• Beckman Coulter Granted FDA EUA for COVID-19 Inflammatory Response Immunoassay

• New Diagnostic Tool Identifies and Treats COVID-19 Patients at Serious Risk of Developing Cytokine Storm

• Vivera Pharmaceuticals Launches Two New COVID-19 Diagnostic Tests for Detection of SARS-CoV-2 Antigens

• Huge COVID-19 Testing Demand to Drive Global Point-of-Care Diagnostics Market to USD 11.7 Billion by 2024